Cargando…

Software compatibility analysis for quantitative measures of [(18)F]flutemetamol amyloid PET burden in mild cognitive impairment

RATIONALE: Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer’s disease pathogenesis. In clinical practice, trained readers will visually categorise positron emission tomography (PET) scans as either Aβ positive or negative. However, adjunct quantitative analysis i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pemberton, Hugh G., Buckley, Christopher, Battle, Mark, Bollack, Ariane, Patel, Vrajesh, Tomova, Petya, Cooke, David, Balhorn, Will, Hegedorn, Katherine, Lilja, Johan, Brand, Christine, Farrar, Gill
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209381/ https://www.ncbi.nlm.nih.gov/pubmed/37225974 http://dx.doi.org/10.1186/s13550-023-00994-3

Ejemplares similares

Estimation of amyloid distribution by [(18)F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition
por: Thal, Dietmar Rudolf, et al.
Publicado: (2018)

Quantification of amyloid PET for future clinical use: a state-of-the-art review
por: Pemberton, Hugh G., et al.
Publicado: (2022)

Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer’s disease
por: Ikonomovic, Milos D., et al.
Publicado: (2020)

Is there a difference in regional read [(18)F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?
por: Farrar, Gill, et al.
Publicado: (2019)

Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods
por: Battle, Mark R., et al.
Publicado: (2018)

Initial Physician Experience with [(18)F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan
por: Hattori, Naoya, et al.
Publicado: (2020)

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
por: Ikonomovic, Milos D., et al.
Publicado: (2016)

A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [(18)F]flutemetamol amyloid PET images
por: Bucci, Marco, et al.
Publicado: (2021)

Visual assessment of [(18)F]flutemetamol PET images can detect early amyloid pathology and grade its extent
por: Collij, Lyduine E., et al.
Publicado: (2021)

Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [(18)F] flutemetamol amyloid PET study
por: Hanseeuw, Bernard J., et al.
Publicado: (2020)

Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments
por: Cho, Soo Hyun, et al.
Publicado: (2020)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Author Correction: Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments
por: Cho, Soo Hyun, et al.
Publicado: (2021)

Amyloid-Targeting PET Tracer [(18)F]Flutemetamol Accumulates in Atherosclerotic Plaques
por: Hellberg, Sanna, et al.
Publicado: (2019)

Infrequent false positive [(18)F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
por: Ikonomovic, Milos D., et al.
Publicado: (2018)

Validation of an electronic image reader training programme for interpretation of [(18)F]flutemetamol β-amyloid PET brain images
por: Buckley, Christopher J., et al.
Publicado: (2017)

Clinical significance of focal ß-amyloid deposition measured by (18)F-flutemetamol PET
por: Kim, Si Eun, et al.
Publicado: (2020)

Is Amyloid Burden Measured by (18)F-Flutemetamol PET Associated with Progression in Clinical Alzheimer’s Disease?
por: Müller, Ebba Gløersen, et al.
Publicado: (2022)

Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
por: Lilja, Johan, et al.
Publicado: (2019)

The clinical safety, biodistribution and internal radiation dosimetry of flutemetamol ((18)F) injection in healthy Japanese adult volunteers
por: Senda, Michio, et al.
Publicado: (2015)

Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
por: Salloway, Stephen, et al.
Publicado: (2017)

Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2019)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result
por: Westwood, Sarah, et al.
Publicado: (2018)

Appropriate reference region selection of (18)F-florbetaben and (18)F-flutemetamol beta-amyloid PET expressed in Centiloid
por: Cho, Soo Hyun, et al.
Publicado: (2020)

Assessing Amyloid Pathology in Cognitively Normal Subjects Using (18)F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods
por: Collij, Lyduine E., et al.
Publicado: (2019)

Longitudinal changes in (18)F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations
por: Luckett, Emma S., et al.
Publicado: (2023)

(18)F-flutemetamol positron emission tomography in cardiac amyloidosis
por: Papathanasiou, Maria, et al.
Publicado: (2020)

Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
por: Zwan, Marissa D., et al.
Publicado: (2017)

Longitudinal Assessment of Amyloid-β Deposition by [18F]-Flutemetamol PET Imaging Compared With [11C]-PIB Across the Spectrum of Alzheimer’s Disease
por: Hatashita, Shizuo, et al.
Publicado: (2019)

Assessment of perfusion deficit with early phases of [(18)F]PI-2620 tau-PET versus [(18)F]flutemetamol-amyloid-PET recordings
por: Völter, Friederike, et al.
Publicado: (2022)

Windows software compatibility and hardware troubleshooting
por: Halsey, Mike, et al.
Publicado: (2015)

Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben
por: Son, Hye Joo, et al.
Publicado: (2018)

Image reconstruction methods affect software-aided assessment of pathologies of [(18)F]flutemetamol and [(18)F]FDG brain-PET examinations in patients with neurodegenerative diseases
por: Lindström, Elin, et al.
Publicado: (2020)

In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [(18)F]flutemetamol
por: Snellman, Anniina, et al.
Publicado: (2014)

Cerebellar and Cerebral Amyloid Visualized by [(18)F]flutemetamol PET in Long-Term Hereditary V30M (p.V50M) Transthyretin Amyloidosis Survivors
por: Uneus, Erica Irene, et al.
Publicado: (2022)

La Grecia de nadie : las palabras dentro del mito
por: Bollack, Jean
Publicado: (1999)

A Case of Early Onset Alzheimer's Disease Diagnosed by (18)F Flutemetamol PET Image
por: Kim, Jeong-Hoon, et al.
Publicado: (2018)

Computed Tomography Density and β-Amyloid Deposition of Intraorbital Optic Nerve May Assist in Diagnosing Mild Cognitive Impairment and Alzheimer’s Disease: A (18)F-Flutemetamol Positron Emission Tomography/Computed Tomography Study
por: Wu, Han, et al.
Publicado: (2022)

Temporal and anatomical distribution of (18)F-flutemetamol uptake in canine brain using positron emission tomography
por: Yun, Taesik, et al.
Publicado: (2020)

Early-phase (18)F-FP-CIT and (18)F-flutemetamol PET were significantly correlated
por: An, Young-Sil, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5se64g97tkqesl7934o2ijngs0